Navigation Links
Arpida to Restructure and Focus on Key Projects
Date:11/27/2008

REINACH, Switzerland, November 27 /PRNewswire-FirstCall/ -- Arpida announced today that it is refocusing all projects and priorities around the key strategic asset Iclaprim. The company says this is to be seen as a consequence of the negative recommendation of the U.S. Food and Drug Administration (FDA) advisory board on 20 November 2008 regarding the approval of Iclaprim in the U.S.

In the context of the FDA advisory board's recommendation the Arpida board intends to put the company back on a firm footing through cutting costs considerably. To achieve this, the company views the reduction of the workforce by up to 60 employees as inevitable. A consultation process with all employees has been initiated and will lead to decisions by the Board of Directors which will be communicated on 16 December 2008. Board and Management sincerely regret this measure and would like to point out that the company will endeavour to fully assume its social responsibilities. Contact with public authorities on this issue has been established and a social plan will be presented in time.

Arpida will now thoroughly analyse the situation with external experts to determine the future development of Iclaprim. Basis for this analysis will be the full FDA response to the Iclaprim dossier and the publication of the phase II oral step down therapy trial.

"We were very surprised by this very clear negative ruling by the FDA advisory board", CEO Jurgen Raths said. "In particular we are very upset by the steps we are forced to take in regards to our staff. The advisory board's recommendation has come totally unexpected, because we are still convinced that Iclaprim offers a valuable therapeutic asset for the treatment of complicated skin and skin structure infections (cSSSI), especially where MRSA (resistant bacteria called methicillin-resistant staphylococcus aureus) are involved. We will use the FDA's feedback as well as furthe
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Arpidas iclaprim MAA Accepted for Review by EMEA
2. Arpida Reports Interim Results for Six Months to 30 June 2008
3. Arpida Announces FDA Acceptance of the Iclaprim New Drug Application
4. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
5. Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company
6. Arpida Announces Conference Call on 17 April
7. Arpida Announces Agenda Items for Shareholders Meeting
8. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
9. Arpida Announces Full Year 2007 Financial Results
10. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
11. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... York (PRWEB) August 22, 2014 ... of the interesting and challenging endeavors as the ... highly impervious properties to the foreign substances. Ocular ... possibility of self medication and minimal use of ... molecular weight drugs and provides specific targeting within ...
(Date:8/22/2014)... Research and Markets has announced the addition ... Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - ... The global molecular biology enzymes market was ... to grow at a CAGR of 13.74% to reach ... reagents find applications in a large number of fields ...
(Date:8/22/2014)... Toronto, Canada (PRWEB) August 22, 2014 ... traits in model organisms can be accelerated by ... design and manufacturing technologies, the custom SeqCap EZ ... such research. , Mr. Watson will additionally present ... seen with commercially available human and mouse exome ...
(Date:8/21/2014)... 2014 DNA vaccine pioneer Immunomic ... development of JRC-LAMP-vax, an innovative and safe potential treatment ... studies began this month in Hawaii, moving the world ... The Japanese red cedar releases pollen that causes devastating ... Cedar pollen wreaks similar havoc in Colorado, New Mexico ...
Breaking Biology Technology:Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 3Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4
... pure proteinTHOUSAND OAKS, Calif., Feb. 24 Bone Biologics, ... organization, Aragen Bioscience, has completed development of a recombinant ... recombinant protein. Bone Biologics has been developing the protein ... ten years of research in the lab performed by ...
... Genencor, a division of Danisco A/S, launched Accellerase(R) ... enzyme product. Genencor introduced the product at the ... in San Antonio, TX.Accellerase(R) 1500 is another significant ... made from cellulosic feedstocks, such as agricultural residues ...
... Ohio, Feb. 24 EyeScience Labs has launched ... comprehensive information and education on age-related macular degeneration (AMD) ... progressive, hereditary eye disease that is the leading cause ... the site, visitors can learn about basic eye anatomy, ...
Cached Biology Technology:Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Biosciences 2Genencor Launches Accellerase(R) 1500, Next Step Toward Scale-Up of Cellulosic Ethanol 2EyeScience Launches Comprehensive Online Resource Devoted to Age-Related Macular Degeneration Education and Prevention 2
(Date:8/22/2014)... of captive black rhino reproduction in Europe highlights ... breeding programmes. , Researchers from Chester Zoo, The ... carried out a six-year study which encompassed 90% ... Katie Edwards led the research as part of ... says: "Although some black rhinoceros breed well in ...
(Date:8/22/2014)... 3β-Hydroxysteroid-Δ24 reductase (DHCR24) is a multifunctional ... reticulum and has neuroprotective and cholesterol-synthesizing ... apoptosis caused by amyloid β deposition. ... Liaoning University in China constructed two ... drive DHCR24 expression specifically in neuronal ...
(Date:8/22/2014)... Stanford, CAEveryone,s heard of the birds and the ... flowers that are being fertilized. The fertilization process ... extensive communication between the male and female reproductive ... Stanford, Regensburg, Heidelberg, and Munich, and including Carnegie,s ... discoveries in the chemical signaling process that guides ...
Breaking Biology News(10 mins):Hormone analysis helps identify horny rhinos 2Calcium and reproduction go together 2
... team of scientists led by University of Hawai,i at ... Florida International University, and Alexander Tielens of Leiden Observatory ... form polycyclic aromatic hydrocarbons (PAHs) complex organic molecules ... ultra-cold regions of interstellar space. The team announced their ...
... Rockville, MD The Association for Research in Vision ... Vision Science & Technology (TVST), with an open ... online only, peer-reviewed journal emphasizing multidisciplinary research that bridges ... The new journal will publish manuscripts in ...
... published online in the FASEB Journal ( http://www.fasebj.org ... the intestines may be used to predict a person,s likelihood ... may help reduce heart attack risk. This discovery may lead ... prevent and treat heart attacks. In addition, this research suggests ...
Cached Biology News:UH Manoa researchers discover novel chemical route to form organic molecules 2UH Manoa researchers discover novel chemical route to form organic molecules 3UH Manoa researchers discover novel chemical route to form organic molecules 4ARVO launches new journal on translational research 2The microbiome and disease: Gut bacteria influence the severity of heart attacks in rats 2
...
Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
Biology Products: